KLK3 and prostate carcinoma: PCWG has evolved from PCWG1 (1999) which standardized PSA outcomes in castration-resistant prostate cancer to PCWG2 (2008), emphasizing drug efficacy assessment by control/relieve/eliminate or prevent/delay end points, such as spread to additional sites using conventional imaging [12].